DS
Therapeutic Areas
Humacyte Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Symvess™ (Acellular Tissue Engineered Vessel) | Vascular Trauma Repair | Approved |
| Acellular Tissue Engineered Vessel (ATEV/HAV) | Arteriovenous (AV) Access for Hemodialysis | Phase 3 |
| BioVascular Pancreas™ | Type 1 Diabetes | Preclinical |
| Lung | Lung Disease / Replacement | Preclinical |
| Urinary Conduit | Urinary Diversion | Preclinical |
| Tracheal Replacement | Tracheal Defects/Disease | Preclinical |
| Esophageal Replacement | Esophageal Defects/Disease | Preclinical |
Leadership Team at Humacyte
LE
Laura E. Niklason, M.D., Ph.D.
Founder, President, Chief Executive Officer
SP
Shamik Parikh, M.D.
Chief Medical Officer
SO
Sabrina Osborne, GPHR, SPHR, CPC
Chief People Officer
LM
Lisa Molyneux
Executive Vice President, Enterprise Planning & Analysis
HC
Heather Connelly, Ph.D.
Executive Vice President, Regulatory Affairs & Quality